A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Study Title
A Phase 1b, Open-Label Trial to Assess Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Teva Identifier
TV53408-IMM-10209
ClinicalTrials.gov Identifier
NCT06625177
Study Status
Recruiting
Trial Condition(s)
Vitiligo
Interventions
Drug: TEV-53408

Study Description

Primary objectives:
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo.
Another primary objective is to evaluate the efficacy of TEV-53408.

Secondary objectives:
A secondary objective is to further evaluate the safety of TEV-53408.
The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.

Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 75 Years
Trial Duration
November 11, 2024 - June 05, 2027
Phase
Phase 1

Study Type

Interventional